Hemologic B.V. is a Dutch R&D company, part of The Surgical Company Group (Amersfoort, The Netherlands) and aims to introduce a novel non-invasive cardiac diagnostic and monitoring technology, for use in the assessment of the hemodynamic functioning of the heart by measuring atrial and ventricular filling curves. The Hemologic Cardiac Profiler is expected to offer a non-invasive, real time, wireless, remote, continuous measurement of hemodynamic parameters under a wide range of in-and outpatient examination settings. As such, the Hemodynamic Cardiac Profiler addresses the need of physicians to obtain hemodynamic data of patients, as simple and fast as obtaining an ECG, and early on in the examination process. Hemologic plans to license its technology to parties in the field of cardiac diagnostics and vital signs monitoring.
| Website | http://www.hemologic.com |
| Employees | 17 (3 on RocketReach) |
| Industry | Medical Equipment Manufacturing |
| Keywords | Cardiac Diagnostics, Hemodynamic Monitoring, Non Invasive Diagnostics, Heart Health Technology, Cardiology Technology, Medical Device Technology, Diagnostic Medical Devices, Non Invasive Technology, Medical Device Innovation, Remote Patient Monitoring, Digital Health Technology, Health Monitoring Systems |
| Competitors | Johnson & Johnson, Thermo Fisher Scientific, Novartis, Bristol Myers Squibb, Genentech, Amgen, Gilead Sciences, Bio-Rad Laboratories, Repligen Corporation, MedImmune +38 more (view full list) |
Looking for a particular TSCI employee's phone or email?
Barry Maashoff is the CEO of TSCI.
3 people are employed at TSCI.